Brentuximab ELISA Kit High-Sensitivity Detection for ADC Therapeutic Monitoring

Overview

Brentuximab vedotin is an antibody-drug conjugate that represents a landmark advancement in the treatment of CD30-positive lymphomas. The construct consists of a chimeric immunoglobulin gamma one (IgG1) monoclonal antibody specific for CD30 conjugated to the potent anti-mitotic agent monomethyl auristatin E via a protease-cleavable valine-citrulline linker. This innovative design combines the targeting precision of monoclonal antibody therapy with the cytotoxic potency of traditional chemotherapy, delivering the payload directly to CD30-expressing tumor cells while sparing normal tissues.The successful development and clinical use of Brentuximab vedotin depend on robust bioanalytical methods to support pharmacokinetic studies, immunogenicity assessments, and therapeutic monitoring. Unlike conventional monoclonal antibodies, antibody-drug conjugates present unique bioanalytical challenges because the analyte exists in multiple forms including total antibody, conjugated antibody, and free payload. Accurate quantification of the intact conjugate is essential for understanding the relationship between exposure and response. In addition to drug quantification, immunogenicity monitoring is critical for antibody-drug conjugate therapies. Patients may develop anti-Brentuximab antibodies following treatment, which can alter drug pharmacokinetics, reduce efficacy, and potentially trigger adverse events. Reliable detection of these anti-drug antibodies is therefore an essential component of comprehensive bioanalytical characterization.

Figure 1. Overview of Brentuximab ELISA Kit High-Sensitivity Detection for ADC Therapeutic Monitoring Characteristics. Figure 1.Brentuximab ELISA Kit High-Sensitivity Detection for ADC Therapeutic Monitoring.

Brentuximab Vedotin A CD30-Targeting Antibody-Drug Conjugate

CD30 as a Therapeutic Target in Lymphoma

CD30 is a transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily. Under normal physiological conditions, CD30 expression is highly restricted, found primarily on activated T cells and B cells. This limited expression pattern in normal tissues makes CD30 an attractive target for therapeutic intervention, as on-target off-tumor toxicity is expected to be minimal. In contrast to normal tissues, CD30 is overexpressed on the surface of malignant cells in classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma, as well as in other CD30-positive lymphoproliferative disorders. The high level and restricted pattern of CD30 expression provide an excellent therapeutic window for CD30-targeting agents. Upon antibody binding, CD30 rapidly internalizes, a property that is essential for antibody-drug conjugate approaches that require intracellular delivery of cytotoxic payloads.

Antibody-Drug Conjugate Technology

Antibody-drug conjugates represent an innovative class of cancer therapeutics that combine the specificity of monoclonal antibodies with the potency of cytotoxic small molecules. The construct comprises three components: the antibody that provides targeting specificity, the linker that attaches the payload to the antibody, and the payload that exerts the cytotoxic effect. The antibody component of Brentuximab vedotin is a chimeric IgG1 monoclonal antibody with high affinity and specificity for human CD30. The chimeric nature reduces immunogenicity compared to murine antibodies while maintaining strong binding characteristics. The antibody mediates internalization upon target engagement, delivering the conjugate to the lysosomal compartment where payload release occurs.

Bioanalytical Monitoring of Brentuximab Vedotin

Bioanalytical Monitoring of Brentuximab Vedotin	Details
Unique Challenges of ADC Quantification	Quantification of antibody-drug conjugates presents unique challenges compared to conventional monoclonal antibodies. The conjugate is a heterogeneous mixture with variable drug-to-antibody ratios. The intact conjugate may undergo deconjugation in circulation or during sample handling. For pharmacokinetic characterization, measurement of the intact conjugate is critical, as this represents the pharmacologically active species capable of delivering payload to target cells.
Importance of Immunogenicity Monitoring	As with all biotherapeutic products, treatment with Brentuximab vedotin may elicit immune responses resulting in the production of anti-drug antibodies. Anti-Brentuximab antibodies can alter drug pharmacokinetics, reduce efficacy, and potentially trigger infusion-related reactions. Accurate detection and characterization of anti-Brentuximab antibodies are essential for understanding the immunogenicity profile of this antibody-drug conjugate.

Clinical Applications in CD30-Positive Lymphomas

Brentuximab vedotin is approved for the treatment of classical Hodgkin lymphoma patients who have relapsed after autologous stem cell transplantation or who are ineligible for transplantation. In this setting, Brentuximab vedotin has demonstrated response rates exceeding seventy percent, with a meaningful proportion of patients achieving complete remissions. For systemic anaplastic large cell lymphoma, Brentuximab vedotin is approved as first-line therapy based on a phase three trial demonstrating superior progression-free survival compared to standard chemotherapy. The approval of Brentuximab vedotin as a first-line treatment represents a significant advance for patients with this aggressive lymphoma subtype. The safety profile of Brentuximab vedotin includes peripheral neuropathy, neutropenia, and infusion-related reactions. The peripheral neuropathy is related to monomethyl auristatin E exposure and is generally reversible upon dose reduction or discontinuation in most patients.

Brentuximab ELISA Kit

The Brentuximab ELISA Kit is designed for the quantitative determination of intact Brentuximab vedotin concentrations in human serum, plasma, or other biological matrices. This kit is optimized for pharmacokinetic studies and therapeutic monitoring in ADC research.

Key Features

High Sensitivity: Quantifies Brentuximab at very low concentrations, enabling characterization of terminal elimination phases.
Wide Dynamic Range: Accommodates samples from different time points across the full pharmacokinetic profile.
Intact Conjugate Specificity: Detects fully functional antibody-drug conjugate, representing the pharmacologically active species.
Validated Matrix Compatibility: Optimized for human serum and plasma with minimal matrix interference.

Rabbit Anti-Brentuximab Monoclonal Antibody

The Rabbit Anti-Brentuximab Monoclonal Antibody is a specialized research reagent designed for the detection and quantification of Brentuximab vedotin in biological samples. This rabbit monoclonal antibody serves as a critical tool for pharmacokinetic studies, immunogenicity assessment, and the development of ligand binding assays.

Key Features

High Specificity: Rabbit monoclonal antibody specific for Brentuximab with minimal cross-reactivity to other antibody-drug conjugates or therapeutic antibodies.
High Affinity: Sub-nanomolar binding affinity enables sensitive detection in complex biological matrices.
Monoclonal Format: Consistent lot-to-lot reproducibility from a defined clonal cell line.
Versatile Applications: Suitable for ELISA development, pharmacokinetic assays, and immunogenicity testing.

Applications

Development of in-house pharmacokinetic assays for Brentuximab vedotin
Capture antibody for sandwich ELISA formats
Detection antibody for immunogenicity assessment
Research studies of ADC disposition and clearance
Quality control testing for research-grade ADC preparations

Conclusions

Brentuximab vedotin represents a transformative antibody-drug conjugate therapy for CD30-positive lymphomas, combining targeted delivery with potent cytotoxicity. Reliable bioanalytical methods are essential for supporting the development and clinical use of this important therapeutic. The Brentuximab ELISA Kit provides a high-sensitivity solution for drug quantification, enabling pharmacokinetic characterization and therapeutic monitoring. The Anti-Blinatumomab ELISA Kit supports immunogenicity assessment in related bispecific antibody research. The Rabbit Anti-Brentuximab monoclonal antibody offers a versatile research reagent for in-house assay development. Together, these products provide a comprehensive toolkit for ADC bioanalysis.

Reagent Solutions

Brentuximab ELISA Kit

Cat. No.	Product Name	Species Reactivity	Detection Method
DEIA-JY25256	Free Anti-CD30 ADC (Brentuximab) ELISA Kit	Human	sELISA	Inquiry
DEIA-JY25382	Brentuximab vedotin (ADC) ELISA Kit	N/A	sELISA	Inquiry

Anti-Brentuximab Antibody

Target	Cat. No.	Product Name	Host	Isotype	Application
TNFRSF8	CABT-ZB1149	Human Anti-Brentuximab vedotin monoclonal antibody, clone AbD39649ca	Human	Fab	ELISA	Inquiry
	CABT-ZB1150	Human Anti-Brentuximab vedotin monoclonal antibody, clone AbD39650ia	Human	IgG1,	ELISA	Inquiry
	CABT-ZB1151	Human Anti-Brentuximab vedotin monoclonal antibody, clone AbD39655ia	Human	IgG1,	ELISA	Inquiry
	CABT-ZB1152	Human Anti-Brentuximab vedotin monoclonal antibody, clone AbD39659ia	Human	IgG1,	ELISA	Inquiry
	CABT-ZB1187	Rabbit Anti-Brentuximab monoclonal antibody, clone 2262C	Rabbit	IgG	WB, ELISA, FC	Inquiry
	CABT-ZB1188	Rabbit Anti-Brentuximab monoclonal antibody, clone 2262C [Alexa Fluor 488]	Rabbit	IgG	FC	Inquiry
	CABT-CS366	Human Anti-Human CD30 (brentuximab vedotin biosimilar) Monoclonal antibody, clone brentuximab vedotin	Chimeric	IgG1	ELISA	Inquiry

Inquiry Basket

Loading ......

Inquiry